The world's first tumor cell microparticle-mediated targeted biochemotherapy.

Since 2016, the Team led by Professor JIN Yang of  Union Hospital Affiliated to TJMC of HUST, has been the first to apply to individualized targeting of autologous tumor cell-derived microparticle-encapsulated chemotherapeutic drugs for treating advanced lung cancer in clinical practice, which has been successfully recognized by global peers and registered international patent.

The results of the clinical treatment of 43 patients indicated that there were no significant adverse reactions before and after treatment, and the safety was good; the tumor cell killing was obvious, showing obvious therapeutic effects of advanced lung cancer and anti-tumor immune effects.